ALPS Advisors’s Gilead Sciences GILD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$7.03M Sell
50,414
-3,697
-7% -$518K 0.03% 211
2025
Q4
$6.64M Buy
54,111
+198
+0.4% +$24.1K 0.04% 217
2025
Q3
$5.98M Buy
53,913
+34,083
+172% +$3.87M 0.03% 224
2025
Q2
$2.2M Buy
19,830
+2,234
+13% +$238K 0.01% 354
2025
Q1
$1.97M Buy
17,596
+190
+1% +$19.6K 0.01% 352
2024
Q4
$1.61M Sell
17,406
-291,007
-94% -$26.2M 0.01% 375
2024
Q3
$25.9M Sell
308,413
-84,455
-21% -$6.44M 0.17% 69
2024
Q2
$27M Buy
392,868
+38,400
+11% +$2.56M 0.19% 58
2024
Q1
$26M Buy
354,468
+24,189
+7% +$1.86M 0.18% 63
2023
Q4
$26.8M Sell
330,279
-18,412
-5% -$1.43M 0.21% 58
2023
Q3
$26.1M Buy
348,691
+10,670
+3% +$821K 0.22% 51
2023
Q2
$26.1M Sell
338,021
-10,747
-3% -$857K 0.23% 66
2023
Q1
$28.9M Buy
348,768
+22,189
+7% +$1.84M 0.26% 49
2022
Q4
$28M Sell
326,579
-93,658
-22% -$7.42M 0.25% 52
2022
Q3
$25.9M Sell
420,237
-110,237
-21% -$6.95M 0.25% 59
2022
Q2
$32.8M Buy
530,474
+113,539
+27% +$7.03M 0.32% 41
2022
Q1
$24.8M Buy
416,935
+80,853
+24% +$5.17M 0.27% 69
2021
Q4
$24.4M Sell
336,082
-444
-0.1% -$30.6K 0.27% 62
2021
Q3
$23.5M Sell
336,526
-28,825
-8% -$2.03M 0.23% 74
2021
Q2
$25.2M Sell
365,351
-9,757
-3% -$652K 0.22% 69
2021
Q1
$24.2M Buy
375,108
+36,155
+11% +$2.33M 0.24% 73
2020
Q4
$19.7M Buy
338,953
+59,664
+21% +$3.6M 0.22% 102
2020
Q3
$17.6M Buy
279,289
+9,119
+3% +$632K 0.26% 87
2020
Q2
$20.8M Sell
270,170
-40,070
-13% -$3.07M 0.28% 56
2020
Q1
$23.2M Sell
310,240
-233,564
-43% -$16.1M 0.36% 46
2019
Q4
$35.3M Buy
543,804
+6,135
+1% +$400K 0.28% 68
2019
Q3
$34.1M Buy
537,669
+3,416
+0.6% +$223K 0.27% 71
2019
Q2
$36.1M Sell
534,253
-60,185
-10% -$3.96M 0.27% 78
2019
Q1
$38.6M Sell
594,438
-25,712
-4% -$1.71M 0.27% 71
2018
Q4
$38.8M Sell
620,150
-47,101
-7% -$3.29M 0.3% 56
2018
Q3
$51.5M Sell
667,251
-25,839
-4% -$1.95M 0.34% 48
2018
Q2
$49.1M Buy
693,090
+53,152
+8% +$3.75M 0.32% 57
2018
Q1
$48.2M Sell
639,938
-32,101
-5% -$2.55M 0.38% 51
2017
Q4
$48.1M Buy
672,039
+646,350
+2,516% +$49.1M 0.33% 64
2017
Q3
$2.08M Buy
25,689
+1,949
+8% +$149K 0.01% 184
2017
Q2
$1.68M Buy
23,740
+3,481
+17% +$232K 0.01% 192
2017
Q1
$1.38M Buy
20,259
+10,761
+113% +$757K 0.01% 194
2016
Q4
$680K Buy
9,498
+1,353
+17% +$101K 0.01% 247
2016
Q3
$644K Buy
8,145
+713
+10% +$57.9K 0.01% 245
2016
Q2
$620K Buy
7,432
+2,661
+56% +$236K 0.01% 226
2016
Q1
$438K Buy
4,771
+369
+8% +$33.3K ﹤0.01% 436
2015
Q4
$445K Sell
4,402
-100
-2% -$10.4K ﹤0.01% 554
2015
Q3
$4.42K Sell
4,502
-755
-14% -$83.9K ﹤0.01% 595
2015
Q2
$615K Buy
5,257
+82
+2% +$8.96K 0.01% 282
2015
Q1
$508K Buy
5,175
+140
+3% +$14.2K ﹤0.01% 554
2014
Q4
$475K Sell
5,035
-682
-12% -$70.5K ﹤0.01% 490
2014
Q3
$609K Sell
5,717
-2,150
-27% -$211K ﹤0.01% 247
2014
Q2
$652K Buy
7,867
+200
+3% +$15.6K 0.01% 275
2014
Q1
$543K Sell
7,667
-23
-0.3% -$1.8K 0.01% 521
2013
Q4
$620K Buy
7,690
+3,710
+93% +$258K 0.01% 194
2013
Q3
$250K Buy
+3,980
New +$238K ﹤0.01% 424

Other funds holding GILD

ALPS Advisors's GILD Position: Q1 2026 in Review

ALPS Advisors reduced its Gilead Sciences (GILD) stake by 6.8% in Q1 2026, selling an estimated $518K and leaving 50,414 shares worth $7.03M. The position accounts for 0.03% of the portfolio, ranked #211.

ALPS Advisors first reported a position in GILD in Q3 2013 and has held it in 51 quarters since. The position peaked at $51.5M in Q3 2018. 2,309 funds tracked by Wall St. Rank hold GILD as of Q1 2026.

  • ALPS Advisors held 50,414 shares of Gilead Sciences worth $7.03M as of Q1 2026.
  • ALPS Advisors sold 3,697 Gilead Sciences shares in Q1 2026, an estimated $518K.
  • Gilead Sciences made up 0.03% of ALPS Advisors's portfolio in Q1 2026, its #211 holding.
  • ALPS Advisors first reported a position in Gilead Sciences in Q3 2013 and has held it in 51 quarters since.
  • ALPS Advisors's Gilead Sciences position peaked at $51.5M in Q3 2018.
  • 2,309 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.

Based on ALPS Advisors's 13F filing for Q1 2026, filed 8 May 2026.